Slingshot members are tracking this corporate initiative:
Teva (TEVA) and South Korean Celltrion Enter into Exclusive Partnership to Commercialize Biosimilars to Rituxan and Herceptin in the U.S and Canada
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Oct 06, 2016 Projected Implementation: Q1, 2017 Relevance Tracked Until: Q1, 2019
Don’t see a project related to the strategic initiative you care about?
Related Keywords Exclusive Partnership, Commercialize, Biosimilars, Rituxan, Herceptin, Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Her2-overexpressing Breast Cancer, Her2-overexpressing Metastatic Gastric, Gastroesophageal Junction Adenocarcinoma